COTA to Accelerate Life Sciences Impact With Addition of Christine Kawiecki from IBM Watson Health
With more than 25 years of healthcare experience, Christine Kawiecki joins the COTA, Inc. team to support business growth as life sciences companies are increasingly turning to real-world data to accelerate drug development in a post-pandemic world.
Connecting Providers, Patients, and Life Sciences to Drive Scientific Breakthroughs
Despite having shared goals like improving patient outcomes with new and life-saving treatments, providers and life science companies operate as separate entities, making it difficult to bring blockbuster drugs out of the lab and into the real world. Companies like COTA help solve this problem.
The Questions You Should Be Asking When Evaluating Real-World Data
With a thriving data marketplace and rising enthusiasm, it’s easy to get excited by promises and possibilities of what real-world data (RWD) has to offer, but not all RWD is created equal and it’s important to remember that quality is more important than quantity
Data Standardizations Support Collaboration Across RWD Stakeholders
Most real-world data (RWD) sets aren’t usable directly from the source. Adopting established standards to curate reliable, sharable insights is key for unleashing the potential of rich data assets. Read how COTA is working with HemOnc.org, OMOP, and Health Language to create the deepest, longitudinal, highest quality RWD to drive cancer research.
COTA and MedStar Health Partner To Drive Scientific Research and Expedite Delivery of Innovative Cancer Treatments
MedStar Health will leverage COTA’s real-world data expertise to deliver more precise care for cancer patients
Making a Difference for Cancer Patients with Hybrid and External Control Arms in Clinical Trials
While the traditional approach of studying control and intervention arms concurrently is an effective way to bring new treatment options to patients, the growing availability of high-quality real-world data (RWD) is changing the way we can accelerate results.
Abstracts Accepted for Publication at ASCO 2021
Three abstracts submitted by COTA and various collaborators have been accepted for publication at this year’s meeting. These abstracts demonstrate COTA’s commitment to working with all stakeholders – across healthcare – to bring clarity to cancer care with real-world data.
Working Together to Improve Outcomes: Applying Lessons from Oncology Collaborations to the COVID-19 Pandemic
Leveraging RWD to gain insight into cancer health disparities affecting underserved populations is key to ensuring equitable access, care, and outcomes for all patients.
Miruna Sasu, Ph.D, MBA — Former Head of Johnson & Johnson’s Clinical Trial Feasibility and Advanced Analytics Team — Joins COTA To Drive Clarity in Cancer Care
In her new role as Chief of Life Science Strategy, Miruna will play a critical role in setting the strategy and executing the solutions delivery to meet critical needs in partnership with life science companies to drive efficient and optimal drug development.
COTA Adds New Life Sciences Leadership to Support Growth in Demand for Oncology Real-World Data
To support growing demand for oncology real-world data, COTA is honored to announce a new addition to the team – Paige Whitney. Paige will serve as Vice President of Life Sciences at COTA.
